Other Information
−Removed: During the three months ended September 30, 2025, no director or executive officer adopted , modified, or terminated any trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.
+Added: As disclosed in the table below, during the three months ended March 31, 2026, certain of our directors and/or executive officers adopted plans for trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act.
+Added: Name Position Date of Plan Adoption Scheduled End Date of Trading Arrangement (a)
+Added: Total Number of Securities to Be Sold Under the Plan
+Added: 2/25/2026 12/30/2026 1,929
+Added: Goldstein, M.D.
+Added: 2/5/2026 11/30/2026 1,929
+Added: Kathryn Guarini, Ph.D.
+Added: 2/13/2026 2/5/2027 1,600
+Added: Marion McCourt
+Added: Executive Vice President, Commercial
+Added: 2/17/2026 5/5/2027 6,989
+Added: (a) The trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed
Exhibit Number Description
4 unchanged sentences
101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"):
−Removed: (i) the registrant's Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024;
−Removed: (ii) the registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three and nine months ended September 30, 2025 and 2024;
−Removed: (iii) the registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2025 and 2024;
−Removed: (iv) the registrant's Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024;
+Added: (i) the registrant's Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025;
+Added: (ii) the registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2026 and 2025;
+Added: (iii) the registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2026 and 2025;
+Added: (iv) the registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025;
and (v) the notes to the registrant's Condensed Consolidated Financial Statements.
2 unchanged sentences
REGENERON PHARMACEUTICALS, INC.
−Removed: October 28, 2025 By:
+Added: April 29, 2026 By:
/s/ Christopher Fenimore
4 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.